Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | VCP | P55072 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2340566 | 0.88 | LMNA (0.38) | ALDH1A1ROCK2MEN1KMT2AKDM4E | |
| SCHEMBL2347037 | 0.88 | MEN1 (0.40) | ALDH1A1ADORA2AMEN1HPGDKMT2A | |
| SCHEMBL4699279 | 0.87 | ALPL (0.38) | ALPLMAPTALDH1A1GAAADORA2A | |
| SCHEMBL4789607 | 0.85 | GSK3B (0.41) | ALDH1A1ROCK2ROCK1MAPK1CYP2C9 | |
| SCHEMBL4704287 | 0.85 | MAPT (0.43) | MAPTALDH1A1ROCK2MEN1HPGD | |
| SCHEMBL18342388 | 0.78 | KMT2A (0.40) | MAPTALDH1A1GAAMEN1HPGD | |
| SCHEMBL8010956 | 0.76 | LTA4H (0.45) | MAPTALDH1A1GAAMEN1HPGD | |
| SCHEMBL4702018 | 0.75 | NOS1 (0.46) | — | |
| SCHEMBL4702008 | 0.75 | NOS1 (0.46) | — | |
| SCHEMBL15231211 | 0.75 | CACNA1B (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1527068-B1 | NOVEL ARYLIMIDAZOLE DERIVATIVES, THEIR USE AS NO-SYNTASE INHIBITORS AND AS MODULATORS OF SODIUM CHANNELS | SOD CONSEILS RECH APPLIC (FR) | 2008-01-09 | — | — | EP | disclosed |
| US-7192975-B2 | Arylimidazole derivatives, preparation and therapeutic used thereof | SOCIETE DE CONSEILS DE RECHERCHES ET D''APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-03-20 | — | — | US | disclosed |
| US-20050234118-A1 | Novel aryllimidazole derivatives, preparation and therapeutic used thereof | IPSEN PHARMA S.A.S. (FR) | 2005-10-20 | — | — | US | disclosed |
| EP-1527068-A2 | NOVEL ARYLIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004011402-A2 | NOVEL ARYLIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234118-A1 | Novel aryllimidazole derivatives, preparation and therapeutic used thereof | OPRL1, CBR3, SCN5A | ALPL 3260/4885MAPT 4735/4885ALDH1A1 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.